MedPath

An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence

Phase 3
Completed
Conditions
Urinary Incontinence
Interventions
Device: bion
Registration Number
NCT00080470
Lead Sponsor
Boston Scientific Corporation
Brief Summary

This clinical trial is being conducted to investigate the safety and effectiveness of a new device designed to treat urinary urge incontinence in those patients who have tried and failed two or more conservative therapies.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
148
Inclusion Criteria
  1. Age 18 years and above.
  2. Diagnosed with urinary urge incontinence.
  3. Have no reported history of urethral obstruction/stricture, bladder calculi or bladder tumor.
  4. Have normal upper urinary tract function.
  5. Be capable of giving informed consent.
  6. Be capable and willing to follow all study related procedures.

Key

Exclusion Criteria
  1. Have any active implantable device regardless of whether stimulation status is ON or OFF.
  2. Are pregnant as confirmed by a urine pregnancy test or plan to become pregnant during the following 12 months period.
  3. Less than one year post partum and/or are breast-feeding.
  4. Have any passive implant that contains metal or electrically conductive materials.
  5. Have conditions requiring Magnetic Resonance Imaging (MRI) evaluation.
  6. Have conditions requiring diathermy procedures.
  7. Have an inability to operate the bion Remote Control and bion Recharging System either by self or caregiver.
  8. Have diabetes with peripheral nerve involvement or have severe uncontrolled diabetes.
  9. Have history of coagulopathy or bleeding disorder.
  10. Have a history of pelvic pain as primary diagnosis.
  11. Have anatomical restrictions such that the study device placement is not possible.
  12. Are currently participating or have participated within the past 30 days in any clinical investigation involving or impacting urinary or renal function.
  13. Have a life expectancy of less than 1 year.
  14. Cannot independently comprehend and complete the QoL questionnaires.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2bionNo Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
1bionStimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
Primary Outcome Measures
NameTimeMethod
Number of Leaks Per Day12 months
Freedom From Major Complications5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (11)

Arizona Health Sciences Center (University of Arizona)

🇺🇸

Tucson, Arizona, United States

Bladder Control Center of Norwalk

🇺🇸

Norwalk, Connecticut, United States

The Pelvic and Sexual Health Institute (affiliated with Graduate Hospital)

🇺🇸

Philadelphia, Pennsylvania, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

Sound Urological Associates

🇺🇸

Edmonds, Washington, United States

The Department of Urology, Stanford University Medical Center

🇺🇸

Stanford, California, United States

Cornerstone Medical Specialty Center

🇺🇸

Woodbury, Minnesota, United States

Milestone Medical Research

🇺🇸

Englewood, Colorado, United States

William Beaumont Hospital

🇺🇸

Royal Oak, Michigan, United States

Walter Reed Army Medical Center, Division of Pelvic Medicine and Reconstructive Surgery

🇺🇸

Washington, District of Columbia, United States

Dallas Center for Pelvic Medicine

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath